Albert Cha
CIK 1397906 · last filed 2023-09-28
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$50.56M
Companies
7
Total Filings
32
Lifetime Open-Market Net
$41.68M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| KalVista Pharmaceuticals, Inc. (KALV) Delisted | Director | 1,144,179 | $27.00 | $30.89M | $21.85M | 13 | 2023-09-28 |
| BHVN | Director | 2,049,545 | $13.77 | $28.22M | $7.99M | 3 | 2018-05-03 |
| VYNE Therapeutics Inc. (MNLO) Delisted | Director | 2,606,982 | — | — | $5.00M | 1 | 2018-01-29 |
| ACRS | Director | 4,191,397 | $5.33 | $22.34M | $5.15M | 3 | 2016-07-01 |
| Sierra Oncology, Inc. (DNAI) Delisted | Director | 2,064,308 | — | — | $3.74M | 1 | 2015-07-21 |
| ALBIREO PHARMA, INC. (BIOD) Delisted | Director | 51,799 | — | — | -$2.05M | 3 | 2008-03-04 |
| BIOFORM MEDICAL INC (BFRM) Delisted | Director | 87,410 | — | — | $0 | 1 | 2007-11-14 |
Recent Filings · Page 2 of 4
32 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-10-02 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-10-03 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-07-30 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Buy (P) | +56,367 | $957.7K | EDGAR |
| 2019-07-19 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Buy (P) | +61,280 | $1.09M | EDGAR |
| 2018-10-05 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-09-12 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Buy (P) | +1,058,824 | $18.00M | EDGAR |
| 2018-05-03 | BHVN | Grant (A) | — | $0 | EDGAR |
| 2018-03-15 | BHVN | Grant (A) | +72,727 | $2.00M | EDGAR |
| 2018-01-29 | VYNE Therapeutics Inc. (MNLO) Delisted | Mixed | +4,011,236 | $5.00M | EDGAR |
| 2017-09-29 | KalVista Pharmaceuticals, Inc. (KALV) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.